EGFR and cancer: In addition, the serum NLR was not correlated with the outcomes of ICI treatment in EGFR‐mutated NSCLC, although the serum NLR was reported to be a potent biomarker according to the benefit of ICI treatments in patients with advanced‐stage cancer.26